RECTAL ABSORPTION OF OMEPRAZOLE FROM SUPPOSITORIES IN RABBITS

被引:4
作者
EUN, KH
LEE, YH
SHIM, CK
机构
[1] SEOUL NATL UNIV,COLL PHARM,KWANAK GU,SEOUL 151742,SOUTH KOREA
[2] LG BIOTECH INST,YUSEONG GU,TAEJON 305380,SOUTH KOREA
关键词
OMEPRAZOLE; RECTAL ABSORPTION; SUPPOSITORY; RABBIT; BIOAVAILABILITY; PEG BASE; WITEPSOL BASE;
D O I
10.1007/BF02976403
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Rectal absorption of omeprazole, a proton pump inhibitor, from suppositories was studied in rabbits. The suppositories were prepared by the conventional melting method with two types of bases, water-soluble polyethylene glycol (PEG) 4000 and oil-soluble Witepsol H15 bases, and administered intrarectally (ir) to rabbits at a dose of 10 mg omeprazole/kg. The plasma omeprazole concentration-time profiles of the two suppositories were compared with those following intravenous (iv) administration of the same dose. There were no significant differences between the two suppositories in bioavailabilities and peak plasma concentrations (C-max). Bioavailabilities and C-max of PEG- and Witepsol suppositories were 30.3 and 33.9%, and 7.0 and 5.6 mu g/ml, respectively. However, PEG suppository showed significantly (P<0.05) shorter time to reach peak plasma concentration (T-max), mean absorption time (MAT) and mean residence time in the plasma (MRT) than Witepsol suppository. The T-max, MRT and MAT were 25.0, 83.0 and 38.5 min for PEG suppository, but were 90.0, 122.5 and 78.0 min for Witepsol suppository, respectively. These differences between the two suppositories could be explained by the difference in the in vitro dissolution rates between the suppositories. The dissolution of omeprazole from PEG suppository was reportedly much faster than that from Witepsol suppository. It suggests that plasma profiles of omeprazole, especially C-max, MAT and MRT, could be controlled by modifying the in vitro dissolution rate of the drug from the suppositories. Above results suggest that rectal suppository is worth developing as an alternative dosage form of omeprazole to the conventional oral preparations which need sophisticated treatments, such as enteric coating, to prevent acid degradation of the drug in the stomach fluid.
引用
收藏
页码:219 / 223
页数:5
相关论文
共 18 条
[1]   IMPROVED PROCEDURE FOR QUANTITATION OF OMEPRAZOLE AND METABOLITES USING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
AMANTEA, MA ;
NARANG, PK .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 426 (01) :216-222
[2]  
CHIOU WL, 1969, CHEM PHARM BULL, V17, P2170
[3]  
CHOI MS, 1995, IN PRESS ARCH PHARM, V18
[4]   SHORT-DURATION TREATMENT OF DUODENAL-ULCER WITH OMEPRAZOLE AND RANITIDINE - RESULTS OF A MULTI-CENTRE TRIAL IN GERMANY [J].
CLASSEN, M ;
DAMMANN, HG ;
DOMSCHKE, W ;
HENGELS, KJ ;
HUTTEMANN, W ;
LONDONG, W ;
REHNER, M ;
SIMON, B ;
WITZEL, L ;
BERGER, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (06) :210-215
[5]   HEALING RATE OF GASTRIC-ULCER AFTER TREATMENT WITH OMEPRAZOLE OR RANITIDINE - RESULTS OF A GERMAN MULTICENTER TRIAL [J].
CLASSEN, M ;
DAMMANN, HG ;
DOMSCHKE, W ;
HUTTEMANN, W ;
LONDONG, W ;
REHNER, M ;
SCHOLTEN, T ;
SIMON, B ;
WITZEL, L ;
BERGER, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (16) :628-633
[6]   DIFFERENCES IN HEALING TENDENCY OF REFLUX ESOPHAGITIS WITH OMEPRAZOL AND RANTIDINE - RESULTS OF AN AUSTRIAN-GERMAN-SWISS MULTICENTER TRIAL [J].
DAMMANN, HG ;
BLUM, AL ;
LUX, G ;
REHNER, M ;
RIECKEN, EO ;
SCHIESSEL, R ;
WIENBECK, M ;
WITZEL, L ;
BERGER, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 111 (04) :123-128
[7]  
KIM HJ, 1993, J KOREAN PHARM SCI, V23, P127
[8]   ANIMAL PHARMACODYNAMICS OF OMEPRAZOLE - A SURVEY OF ITS PHARMACOLOGICAL PROPERTIES INVIVO [J].
LARSSON, H ;
MATTSON, H ;
SUNDELL, G ;
CARLSSON, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 :23-35
[9]  
Lee Chang-Hyun, 1993, Yakhak Hoeji, V37, P370
[10]  
NAKASHIMA M, 1988, JPN J PHARM THER, V19, P667